logo
logo

Acerus Announces Closing Of Acquisition Of Serenity Pharmaceuticals Llc And Acquisition Of Global Rights To Noctiva™

Mar 07, 2022•over 3 years ago

Acquiring Company

Acerus

Acquired Company

Serenity

Science And EngineeringBiotechnologyHealth Care

Description

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced the closing of its previously-announced acquisition of Serenity Pharmaceuticals LLC (“Serenity”), including the global rights to its NoctivaTM brand. Serenity, based in Miami, FL, is a specialty pharmaceutical company focused on developing therapies for diseases associated with voiding disorders and had previously been granted approval by the U.S. Food and Drug Administration (FDA) for its NoctivaTM (desmopressin acetate) nasal spray. Additional details of this transaction can be found in the Company’s filings in the US and Canada.

Company Information

Company

Acerus

About

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories. Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed